ResMed Appoints Michael Farrell as Chief Executive Officer; Robert Douglas Appointed President and Chief Operating Officer

  ResMed Appoints Michael Farrell as Chief Executive Officer; Robert Douglas
               Appointed President and Chief Operating Officer

PR Newswire

SAN DIEGO, Feb. 20, 2013

SAN DIEGO, Feb. 20, 2013 /PRNewswire/ --ResMed Inc. (NYSE: RMD) announced
today that effective March 1, 2013, Michael ("Mick") Farrell will succeed Dr.
Peter C. Farrell as ResMed's chief executive officer (CEO) and be appointed to
its board of directors. Robert ("Rob") Douglas will become ResMed's president
and chief operating officer (COO). Current CEO, chairman of the board and
founder, Dr. Farrell, will become executive chairman. Together, Mr. Farrell
and Mr. Douglas will comprise the office of the CEO and Dr. Farrell will work
together with them on an as-needed basis through the end of calendar year
2013, when he will transition to non-executive chairman. In addition, Dr. Jim
Hollingshead has been named president, Americas.


"A thorough review of potential candidates to succeed Peter was conducted by
the board's CEO succession committee, working closely with the nominating and
governance committee and a top-tier executive search consultancy," commented
Dr. Gary Pace, lead director of ResMed's board and chairman of the board's
succession committee. "It was easily determined that members of the very
talented and experienced team that have driven much of the company's great
success over the past decade would be best suited to lead the company to its
next stages of growth and development. Mick led the team in the Americas that
grew sales over 30 percent during the seven quarters that he was president of
that region. He also established a vision for the organization that extended
beyond driving revenue and market share to include a focus on the number of
lives enhanced by ResMed products. Mick's strengths and accomplishments
leading sales, marketing, business development and commercial strategy teams
equip him well to become ResMed's next CEO. Rob's expertise and excellent
track record of increasing productivity and efficiencies of global operations,
as well as success in growing sales, make him the ideal choice for COO and
president. In addition, he was instrumental in creating our successful
manufacturing presence in both Australia and Singapore. At this time, we also
want to thank Peter for resuming the role of CEO over the past couple of years
and now turning over the helm to Mick and Rob while staying on as executive
chairman of the board."

"I have little doubt that Mick and Rob will build on ResMed's momentum as a
global driving force in sleep and respiratory medicine, and as a leader in the
medical device industry," said Dr. Peter Farrell. "Mick has been with us for
more than 12 years; Rob for more than 11. This is a deeply experienced and
accomplished duo to lead ResMed. They have also played an integral role in
developing and preserving the unique culture established within ResMed which
has proved to be an extremely important component of the success of the
company. The board and I are extremely confident in the ability of our senior
management, as well as the talent at all levels throughout ResMed."

"Rob and I have worked in collaboration with the entire organization at ResMed
for more than a decade to help drive the success of our core business by
producing the best products on the market, becoming the preferred mask brand
by patients and promoting the awareness of sleep-disordered breathing,"
commented Mick Farrell. "I am extremely excited to be taking the reins of a
company that will contribute to the well-being and improved quality of life of
millions of patients suffering from sleep-disordered breathing. Looking
forward, we have huge opportunities to leverage current ResMed offerings and
our product pipeline to change the lives of millions of patients who suffer
from such co-morbidities ascongestive heart failure and chronic obstructive
pulmonary disease. Our future success will be accelerated by ResMed's intense
focus on innovation, breaking down barriers to diagnosis and treatment, and an
emphasis on our culture, which attracts world-class talent who learn to share
our passion for changing lives, one breath at a time."

"I am looking forward to working together with Mick and the rest of the team
to build on the success and achievements of ResMed," said Rob Douglas. "We
are uniquely positioned in healthcare. We improve patients' quality of life,
slow down and even improve other medical co-morbidities, and reduce the cost
of healthcare. I am confident we will continue to succeed in the future." 

About Mick Farrell

Michael "Mick" Farrell, joined ResMed in 2000 and became president, Americas
in 2011, responsible for Americas sales and commercial operations.
Previously, Mick was senior vice president, sleep strategic business unit from
2007 to 2011, where he led the global team that executed the design,
development and launch of the very successful S9^™ platform of flow generator
products. Before that, he held the positions of vice president, marketing for
the Americas and vice president, business development. Before joining ResMed,
Mick worked in management consulting and biotechnology, as well as in
chemicals and steel manufacturing at Arthur D. Little, Genzyme Corporation,
The Dow Chemical Company and BHP Billiton. Mick holds a bachelor of
engineering, with first-class honors, from the University of New South Wales,
a master of science in chemical engineering from the Massachusetts Institute
of Technology (MIT) and an M.B.A. from the MIT Sloan School of Management. He
sits on the board of directors of the American Association for Homecare. Mick
is the son of Dr. Peter Farrell.

About Rob Douglas

Rob Douglas, as chief operating officer, holds full operational responsibility
for ResMed and its subsidiaries and is also now being appointed as president.
He joined ResMed in 2001 as vice president of corporate marketing and has
since excelled in additional ResMed roles including president – Asia Pacific
and chief, global supply operations, responsible for global manufacturing and
commercial distribution and sales operations in the Asia Pacific region; COO –
Asia Pacific; and COO – Sydney. Before joining ResMed, Rob had various roles
at Keycorp, an Australian electronics commerce company, managing strategy and
new business, marketing and research and development. Prior to that, he was
head of operations, project management and engineering at Telectronics Pty
Ltd., an Australian medical electronics company. Rob has a master's of
business administration from Macquarie University, a bachelor's degree in
electrical engineering with first-class honors and a bachelor of science
(computer sciences) from the University of New South Wales.

Jim Hollingshead Becomes President, Americas

As Mick Farrell transitions to the CEO role, current ResMed chief strategy
officer and president, ventures & initiatives strategic business unit, Jim
Hollingshead, will replace Farrell as president, Americas. Jim joined ResMed
in 2010 as vice president of strategy & business development. In 2011 his
role was expanded to include leadership of ResMed ventures & initiatives, the
unit within ResMed responsible for growing early stage businesses. Before
ResMed, Jim spent 18 years in strategy consulting, where he worked across a
wide range of industries, with senior roles at Deloitte Consulting and Monitor
Group. Jim holds a bachelor of arts degree in history and international
relations with distinction from Stanford University, and an MA and PhD in
political science from the University of California at Berkeley, where he was
awarded a prestigious graduate student fellowship by the National Science

ResMed is a global leader in the development, manufacturing and marketing of
medical products for the diagnosis, treatment and management of respiratory
disorders, with a focus on sleep-disordered breathing. The company is
dedicated to developing innovative products to improve the lives of those who
suffer from these conditions and to increasing awareness among patients and
healthcare professionals of the potentially serious health consequences of
untreated sleep-disordered breathing. For more information on ResMed, visit

Statements contained in this release that are not historical facts are
"forward-looking" statements as contemplated by the Private Securities
Litigation Reform Act of 1995. These forward-looking statements, including
statements regarding the company's future revenue, earnings or expenses, new
product development and new markets for the company's products, are subject to
risks and uncertainties, which could cause actual results to materially differ
from those projected or implied in the forward-looking statements. Those
risks and uncertainties are discussed in the company's Annual Report on Form
10-K for its most recent fiscal year and in other reports the company files
with the U.S. Securities & Exchange Commission. Those reports are available
on the company's website.

SOURCE ResMed Inc.

Contact: For news media: Gretchen Griswold, Dir., Global Corporate
Communications Director, +1-858-836-6789; For the financial and investment
community: Constance Bienfait, Director, Investor Relations, +1-858-836-5971;
Brett Sandercock, Chief Financial Officer, +61-2-8884-2090
Press spacebar to pause and continue. Press esc to stop.